| Project/Area Number |
04670752
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | TOKAI UNIVERSITY |
|---|
Principal Investigator |
TOKUDA Yutaka TOKAI UNIV.SCHOOL OF MED., ASSISTANT PROFESSOR, 医学部, 講師 (20163975)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1993: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1992: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | Adoptive immunotherapy / Proto-oncogene / C-erbB-2 / CD4^+ T cell / Bispecific antibody / c-erbB-2 / ヘルパーT細胞 / 乳癌 / Interleukin-2 |
|---|
| Research Abstract |
To develop an efficient strategy for the targeting of anti-tumor effector cells, we prepared bispecific antibody(BSAb)containing anti-CD3 and an anti-c-erbB-2 proto-oncogene product. The prepared BSAb specifically reacts with both c-erbB-2-positive tumor cells and CD3^+CTL.Human CD4^+ helper/killer T cells, induced from peripheral-blood mononuclear cells by activation with immobilized anti-CD3 monoclonal antibody plus IL-2, showed no significant cytotoxicity against tumor cells. However, treatment of human CD4^+ helper/killer cells with the BSAb caused the induction of specific cytotoxicity against c-erbB-2-positive tumor cells. CD4^+ helper/killer cells also produced significant amounts of IL-2 during co-culture with c-erbB-2-positive tumor cells in the presence of the BSAb. Moreover, by combination with the BSAb, CD4^+ helper/killer cells showed a significant in vivo anti-tumor effect against c-erbB-2 positive human cancer cells in severe combined immunodeficiency mice. Our results strongly suggest that the c-erbB-2 proto-oncogene product on human tumor cells may be a good target for BSAb-directed adoptive tumor immunotherapy. Thus, we have established a large-scale culture system of these CD4^+ helper/killer T cells to provide enough number of the cells for future clinical trials.
|
